Logo image of JMP

JMP Group Inc (JMP) Stock Fundamental Analysis

NYSE:JMP -

7.5
+0.02 (+0.27%)
Last: 11/15/2021, 8:51:24 PM
7.49
-0.01 (-0.13%)
After Hours: 11/15/2021, 8:51:24 PM
Fundamental Rating

2

JMP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. JMP has a bad profitability rating. Also its financial health evaluation is rather negative. JMP is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JMP was profitable.
JMP Yearly Net Income VS EBIT VS OCF VS FCFJMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 10M -10M 20M -20M

1.2 Ratios

Industry RankSector Rank
ROA 4.71%
ROE 15.12%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JMP Yearly ROA, ROE, ROICJMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -5 -10 -15

1.3 Margins

Industry RankSector Rank
OM 9.63%
PM (TTM) 6.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JMP Yearly Profit, Operating, Gross MarginsJMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 40 60 80

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, JMP has more shares outstanding
The debt/assets ratio for JMP has been reduced compared to a year ago.
JMP Yearly Shares OutstandingJMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M
JMP Yearly Total Debt VS Total AssetsJMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 200M 400M 600M 800M 1B

2.2 Solvency

A Debt/Equity ratio of 1.03 is on the high side and indicates that JMP has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
JMP Yearly LT Debt VS Equity VS FCFJMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M 100M 150M

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 9800.00% over the past year.
The Earnings Per Share has been decreasing by -6.33% on average over the past years.
Looking at the last year, JMP shows a very strong growth in Revenue. The Revenue has grown by 99.21%.
Measured over the past years, JMP shows a decrease in Revenue. The Revenue has been decreasing by -6.66% on average per year.
EPS 1Y (TTM)9800%
EPS 3Y-3.03%
EPS 5Y-6.33%
EPS Q2Q%123.08%
Revenue 1Y (TTM)99.21%
Revenue growth 3Y-7.62%
Revenue growth 5Y-6.66%
Sales Q2Q%58.42%

3.2 Future

The Earnings Per Share is expected to grow by 30.69% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 29.95% on average over the next years. This is a very strong growth
EPS Next Y35.21%
EPS Next 2Y6.79%
EPS Next 3Y21.98%
EPS Next 5Y30.69%
Revenue Next Year65.99%
Revenue Next 2Y28.13%
Revenue Next 3Y29.13%
Revenue Next 5Y29.95%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JMP Yearly Revenue VS EstimatesJMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
JMP Yearly EPS VS EstimatesJMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

JMP is valuated cheaply with a Price/Earnings ratio of 7.58.
When comparing the Price/Earnings ratio of JMP to the average of the S&P500 Index (27.03), we can say JMP is valued rather cheaply.
A Price/Forward Earnings ratio of 10.61 indicates a reasonable valuation of JMP.
When comparing the Price/Forward Earnings ratio of JMP to the average of the S&P500 Index (22.63), we can say JMP is valued rather cheaply.
Industry RankSector Rank
PE 7.58
Fwd PE 10.61
JMP Price Earnings VS Forward Price EarningsJMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.18
JMP Per share dataJMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

JMP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as JMP's earnings are expected to grow with 21.98% in the coming years.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y6.79%
EPS Next 3Y21.98%

More info and screens

0

5. Dividend

5.1 Amount

JMP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JMP Group Inc

NYSE:JMP (11/15/2021, 8:51:24 PM)

After market: 7.49 -0.01 (-0.13%)

7.5

+0.02 (+0.27%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners0.82%
Ins Owner Change0%
Market Cap157.82M
Analysts45
Price Target7.65 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.58
Fwd PE 10.61
P/S 0.9
P/FCF N/A
P/OCF N/A
P/B 2.24
P/tB N/A
EV/EBITDA 8.18
EPS(TTM)0.99
EY13.2%
EPS(NY)0.71
Fwd EY9.43%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.29
BVpS3.35
TBVpSN/A
PEG (NY)0.22
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.71%
ROE 15.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.63%
PM (TTM) 6.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9800%
EPS 3Y-3.03%
EPS 5Y-6.33%
EPS Q2Q%123.08%
EPS Next Y35.21%
EPS Next 2Y6.79%
EPS Next 3Y21.98%
EPS Next 5Y30.69%
Revenue 1Y (TTM)99.21%
Revenue growth 3Y-7.62%
Revenue growth 5Y-6.66%
Sales Q2Q%58.42%
Revenue Next Year65.99%
Revenue Next 2Y28.13%
Revenue Next 3Y29.13%
Revenue Next 5Y29.95%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A